Differential ability of cells to promote oxidation of low density lipoproteins in vitro

Clinica Chimica Acta

Volumn 269, Issue 2, 1998, Pages 159-173

  Fernando, Ray L ^a   Varghese, Zachariah ^a   Moorhead, John F ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Endothelial cells; Glomerulosclerosis; Human mesangial cells; Low density lipoprotein; Oxidation; Proximal tubular cells

Indexed keywords

LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENDOTHELIUM CELL; FOCAL GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY TUBULE CELL; LIPID OXIDATION; MESANGIUM CELL; MONOCYTE; PRIORITY JOURNAL; UMBILICAL VEIN;

ARTERIOSCLEROSIS; CELL LINE; ENDOTHELIUM, VASCULAR; GLOMERULAR MESANGIUM; HUMANS; KIDNEY TUBULES, PROXIMAL; LIPOPROTEINS, LDL; OXIDATION-REDUCTION;

EID: 0032579130     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(97)00199-X     Document Type: Article

References (43)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
2. Anonymous. Antibodies to oxidised LDL in atherosclerosis. Lancet 1992;339:899-900.
3. Parthasarathy S., Steinberg D., Witztum J.L. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. [Review]. Annu Rev Med. 43:1992;219-225.
4. Smith C., Mitchinson M.J., Aruoma O.I., Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 286:1992;901-905.
5. Hoff H.F., O'Neil J. Extracts of human atherosclerotic lesions can modify low density lipoproteins leading to enhanced uptake by macrophages. Atherosclerosis. 70:1988;29-41.
6. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987;84:5928-5931.
7. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725-7729.
8. Steinberg D., Parthasarathy S., Carew T.E. In vivo inhibition of foam cell development by probucol in Watanabe rabbits. Am J Cardiol. 62:1988;6B-12B.
9. Ylä-Herttuala S., Palinski W., Rosenfeld M.E.et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 84:1989;1086-1095.
10. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989;86:1372-1376.
11. Henriksen T., Mahoney E.M., Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: Recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA. 78(10):1981;6499-6503.
12. Heinecke J.W., Baker L., Rosen H., Chait A. Superoxide-mediated oxidation of low density lipoprotein by arterial smooth muscle cells. J Clin Invest. 77:1986;757-761.
13. Parthasarathy S., Printz D.J., Boyd D., Joy L., Steinberg D. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis. 6:1986;505-510.
14. Lamb D.J., Wilkins G.M., Leake D.S. The oxidative modification of low density lipoprotein by human lymphocytes. Atherosclerosis. 92:1992;187-192.
15. EL-Nahas A.M., Marshall R., Moorhead J.F. Glomeruloatherosis or glomerulosclerosis. J Pathol. 140:1983;155.
16. Diamond J.R. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. [Review]. Kidney Int Suppl. 31:1991;S29-S34.
17. Fernando R.L., Varghese Z., Moorhead J.F. Oxidation of low-density lipoproteins by rat mesangial cells and the interaction of oxidised low density lipoproteins with rat mesangial cells. Nephrol Dial Transplant. 8:1993;512-518.
18. Wheeler D.C., Chana R.S., Topley N., Petersen M.M., Davies M., Williams J.D. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int. 45:1994;1628-1636.
19. Keane W.F., O'Donnell M.P., Kasiske B.L., Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol. 4:1993;187-194.
20. Ong A.C., Moorhead J.F. Tubular lipidosis: epiphenomenon or pathogenic lesion in human renal disease? Kidney Int. 45:1994;753-762.
21. Magil A.B., Frohlich J.J., Innis S.M., Steinbrecher U.P. Oxidized low-density lipoprotein in experimental focal glomerulosclerosis. Kidney Int. 43:1993;1243-1250.
22. Sraer J., Delarue F., Hagege J.et al. Stable cell lines of T-SV4O immortalized human glomerular mesangial cells. Kidney Int. 49:1996;267-270.
23. Graham A., Wood J.L., O'Leary V.J., Stone D. Human (THP-1) macrophages oxidize LDL by a thiol-dependent mechanism. Free Radic Res. 21:1994;295-308.
24. Jaffe E.A. Culture of human endothelial cells. Transplant Proc. 81(12):1984;3883-3887.
25. Markwell M.A., Haas S.M., Bieber L.L., Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 87:1978;206-210.
26. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witztum J.L., Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA. 81:1984;3883-3887.
27. Quinn M.T., Parthasarathy S., Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA. 85:1988;2805-2809.
28. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-2998.
29. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein I in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134-5138.
30. Hessler J.R., Morel D.W., Lewis L.J., Chisolm G.M. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis. 3:1983;215-222.
31. Kaplan R., Aynedjian H.S., Schlondorff D., Bank N. Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol. J Clin Invest. 86:1990;1707-1714.
32. Wheeler D.C., Nair D., Persaud J.W.et al. Effects of dietary fatty acids in an animal model of focal glomerulosclerosis. Kidney Int. 39:1991;930-937.
33. Claus R., Fyrnys B., Deigner H.P., Wolf G. Oxidized low-density lipoprotein stimulates protein kinase C (PKC) and induces expression of PKC-isotypes via prostaglandin-H-synthase in P388D1 macrophage-like cells. Biochemistry. 35:1996;4911-4922.
34. Zhang H., Davis B., Chen X., Jones K.H., Whisler R.L., Cornwell D.G. Effects of oxidized low density lipoprotein on arachidonic acid metabolism in smooth muscle cells. J Lipid Res. 31:1990;551-565.
35. Bank N. Renal hemodynamic consequences of hyperlipidemia. [Review]. Miner Electrolyte Metabol. 19:1993;165-172.
36. Heinecke J.W., Baker L., Rosen H., Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J Clin Invest. 77:1986;757-761.
37. Steinbrecher U.P. Role of superoxide in endothelial-cell modification of low-density lipoproteins. Biochim Biophys Acta. 959:1988;20-30.
38. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 1989;86:1046-1050.
39. Derian C.K., Lewis D.F. Activation of 15-lipoxygenase by low density lipoprotein in vascular endothelial cells. Relationship to the oxidative modification of low density lipoprotein. Prostaglandins Leukotrienes Essent Fatty Acids. 45:1992;49-57.
40. van Hinsbergh V.W., Scheffer M., Havekes L., Kempen H.J. Role of endothelial cells and their products in the modification of low-density lipoproteins. Biochim Biophys Acta. 878:1986;49-64.
41. Cathcart M.K., McNally A.K., Morel D.W., Chisolm G.M. 3rd Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin. J Immunol. 142:1989;1963-1969.
42. McNally A.K., Chisolm 3rd G.M., Morel D.W., Cathcart M.K. Activated human monocytes oxidize low-density lipoprotein by a lipoxygenase-dependent pathway. J Immunol. 145:1990;254-259.
43. Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. [Review]. Am J Kidney Dis. 22:1993;72-82.